Insider buying last 90 days
No open-market insider purchases were filed for RAPP in the last 90 days.
From Form 4 filings, dated to when each was filed.
Every RAPP insider filing, plotted on the chart in Gekko.Open RAPP in Gekko
NASDAQ: RAPP
Rapport Therapeutics (RAPP) Stock Analysis & Forecast
Oct 12 close
$30.15−0.50 (−1.6%)
Gekko Brief
AI summaryOct 12 closeThis week's coverage centers on Rapport Therapeutics' focal epilepsy pipeline, which targets helper proteins alongside receptors in specific brain regions. Alongside this, Guggenheim initiated coverage with a Buy rating and a $65.00 price target, while several reports highlighted insider selling, including CEO Abraham Ceesay's sale of $143,272 in stock on October 6 and 7 under a Rule 10b5-1 plan, alongside related Form 4 and Form 144 filings.
RAPP closed at $30.15, down 1.6% on the day, with its one-month return at -30.9% and three-month return at -27.3%, though the one-year return remains positive at 12.8%. The stock sits between its 50-day average of $42.21 and 200-day average of $35.80. The GekkoIndex reads 67.4, placing RAPP in the Accumulation zone, down 2.1 points over five days. The price stands 34.4% below the Gekko Fair Value of $45.97.
Looking ahead, Rapport reports earnings on 5 November, 23 days out and within a typical 20-trading-day holding window; its last report on 5 August showed an EPS miss against estimate, with a 9.8% reaction, and the company has beaten estimates in 5 of its last 8 quarters. Consensus among 10 analysts remains entirely Buy-rated, with a consensus target of $63.04. No insider, Congress, or unusual options activity appears in the current windows, leaving the earnings date as the primary near-term catalyst to note.
Written by AI from the Oct 12, 2026 close and checked automatically against the figures on this page.
Rapport Therapeutics price vs fair value
Close $30.15200-day averageGekko Fair Value $45.97
Rapport Therapeutics quick facts
- Market cap
- $1.44B
- P/E ratio
- —
- Forward P/E
- —
- EPS, TTM
- −$2.93
- Revenue, TTM
- $20.00M
- Profit margin
- 0%
- Dividend yield
- —
- Beta
- 1.22
- Volume
- 127,114 avg 476,874
- 1-year return
- +12.8%
- Typical daily move
- ±7.5%
- Typical 20-day move
- ±11.5%
- 50-day average
- $42.21
- 200-day average
- $35.80
- Next earnings
- Nov 5 before open
- Shares outstanding
- 47.98M
Rapport Therapeutics swing-trade checklist
Rapport Therapeutics scores 2 supportive, 1 mixed and 1 headwind across the 4 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
2 supportive1 mixed1 headwind
- Trendmixed
Averages disagree
Close $30.15 sits between the 50-day ($42.21) and 200-day ($35.80) averages, or the averages disagree.
See the chart - GekkoIndexsupportive
67.4, Accumulation
Reading 67.4 is in the Accumulation zone.
See the GekkoIndex - Fair valuesupportive
34.4% below
Price is 34.4% below Gekko Fair Value (more than 5% below).
See fair value - Smart moneyno data
No data
No insider, Congress or unusual options activity in the window.
See smart money - Earnings riskheadwind
Reports in 24 days
Reports on Nov 5, 2026, 24 days away — inside a typical 20-trading-day hold.
See earnings - Seasonalityno data
No data
Not enough years of history for a seasonal read.
A description of current data, not a recommendation. How this page works
Rapport Therapeutics stock chart and price history
Rapport Therapeutics closed at $30.15 on Oct 12, 2026, +12.8% over the past year, inside a 52-week range of $23.75 to $52.93.
Close50-day average200-day averageVolume
Use the left and right arrow keys to read daily values.
Performance Breakdown
- 1 month
- −30.9%
- 3 months
- −27.3%
- 6 months
- −13.0%
- 1 year
- +12.8%
The full RAPP chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open RAPP in Gekko
Follow Rapport Therapeutics through every session
Put RAPP on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Track RAPP in GekkoFree for 7 days. No credit card required.
About Rapport Therapeutics
Rapport Therapeutics is a clinical-stage biopharmaceutical company working on small-molecule treatments for disorders of the central nervous system. Its most advanced candidate, RAP-219, is built to block TARPy8-containing AMPA receptors with very high potency, and is being studied as a possible treatment for focal epilepsy as well as peripheral neuropathic pain and bipolar disorder.
Beyond RAP-219, the company is developing RAP-199, a second compound aimed at the same TARPy8 target but with a different chemical and pharmacokinetic makeup. It also has earlier-stage programs built around nicotinic acetylcholine receptors, including one intended for chronic pain and another aimed at hearing loss. As a clinical-stage drug developer, Rapport's work centers on research and trials rather than marketed products at this point.
The company began in 2022 under the name Precision Neuroscience NewCo, Inc. before renaming itself Rapport Therapeutics, Inc. later that year, and it operates out of Boston, Massachusetts. Its shares are listed on the NASDAQ under the ticker RAPP.
- Listed
- NASDAQ
- Sector
- Health technology
- Industry
- Biotechnology
- Website
- rapportrx.com
Rapport Therapeutics GekkoIndex: the smart money zone
Rapport Therapeutics’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 67.4, in the Accumulation zone, down 2.1 points over five sessions.
67.4Accumulation
Down 2.1 points over five sessions.
Reading for Oct 12, 2026
What followed past readings in each zone
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 29 | −4.0% | +5.6% | ||
| Accumulation (current zone) | 172 | +2.9% | +2.5% | ||
| Neutral | 370 | +0.5% | +4.3% | ||
| Distribution | 11 | −2.9% | −0.4% | ||
| Selling | 0 | Not available | |||
Average RAPP share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Accumulation readings averaged +2.2% over 20 days. Past behaviour doesn’t guarantee future results.
Accumulation zone: Institutional interest building. About the five zones →
See every daily GekkoIndex reading plotted over the RAPP price, zone by zone.Track RAPP in Gekko
Is Rapport Therapeutics stock overvalued? Gekko Fair Value
Rapport Therapeutics trades 34.4% below Gekko Fair Value of $45.97, so the shares are undervalued on Gekko’s estimate.
Gekko’s own estimate of what Rapport Therapeutics shares are worth, recalculated every trading day.
$45.97
Gekko Fair Value, Oct 10, 2026
34.4% Undervalued
At the end of Aug 2026 the price was 12.4% below the estimate.
Gekko Fair ValueShare price, month end
Gekko Fair Value on every chart, with the gap to price updating daily.Open RAPP in Gekko
Rapport Therapeutics insider and Congress trading
No open-market insider purchases were filed for Rapport Therapeutics, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
Congress trades last 90 days
No trades in RAPP were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Congress disclosures for RAPP, plotted on the chart in Gekko.Open RAPP in Gekko
Buybacks
Rapport Therapeutics has been buying back its own shares.
- Bought back, quarter ended Jun 30, 2026
- $5K
- As a share of market cap
- 0.00%
From company filings.
Rapport Therapeutics earnings: next date and track record
Rapport Therapeutics reports on Nov 5, 2026, before the open (24 days away), and beat the EPS estimate in 5 of its last 8 reports.
Next earnings report
Nov 5, 2026
Expected before the open, 24 days away
- EPS estimate
- −$1.21
5 of 8reports beat the EPS estimate
±4.9%average move across the report
5 of 8reports followed by a gain
Share-price move across each report
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Aug 5, 2026 | −$1.19 est −$0.96 | — est $2.22M | +9.8% |
| May 7, 2026 | −$0.42 est −$0.71 | $20.00M est $7.50M | +2.6% |
| Mar 10, 2026 | −$0.72 est −$0.67 | — | 0.0% |
| Nov 6, 2025 | −$0.71 est −$0.77 | — | −1.9% |
| Aug 7, 2025 | −$0.75 est −$0.87 | — | −0.4% |
| Mar 11, 2025 | −$0.57 est −$0.62 | — | +21.0% |
| Nov 7, 2024 | −$0.50 est −$0.52 | — | +2.1% |
| Aug 8, 2024 | −$1.70 est −$0.68 | — | +1.1% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Rapport Therapeutics stock forecast and analyst price targets
Analysts’ average 12-month price target for Rapport Therapeutics is $63.04, +109.1% from the last close, from 10 firms rating the stock in the last 90 days.
$63.04consensus 12-month target, +109.1% from the last close
Now $30.15Avg $63.04
Low $50High $75
Each firm’s latest rating in the last 90 days: 10 firms.
Latest analyst actions
| Date | Firm | Target | vs price |
|---|---|---|---|
| Oct 5 | Guggenheim | $65 | +115.6% |
| Oct 1 | BTIG | $75 | +148.8% |
| Sep 23 | William Blair | — | — |
| Sep 23 | H.C. Wainwright | $66 | +118.9% |
| Sep 23 | Raymond James | — | — |
+2.5%average 20-day move after past Accumulation readings
±7.5%typical daily move, from the 14-day average range
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Rapport Therapeutics market cap and key statistics
Rapport Therapeutics’s market cap is $1.44B and revenue of $20.00M over the last twelve months.
Valuation
- Market cap
- $1.44B
- EPS, TTM
- −$2.93
- Gekko Fair Value
- $45.97
Trading
- Volume
- 127,114
- Avg volume, 20 days
- 476,874
- 52-week high
- $52.93
- 52-week low
- $23.75
- Shares outstanding
- 47.98M
Financials
- Revenue, TTM
- $20.00M
- Profit margin
- 0%
- Return on equity
- -40%
- Quarterly earnings growth, YoY
- 0.0%
Risk and income
- Beta
- 1.22
- Typical daily move
- ±7.5%
- Typical 20-day move
- ±11.5%
Rapport Therapeutics stock news this week
Coverage of Rapport Therapeutics this week reads positive: 3 positive, 3 neutral and 1 negative headlines.
- Which Brain Pathways Is Rapport Therapeutics Trying to Tune?Kalkine Media, Oct 11
- Several Rapport Therapeutics Insiders Sell Shares Sending Potential Negative SignalSimply Wall Street, Oct 11
- Form 4 Rapport Therapeutics Inc For: 10 October By Investing.comInvesting.com South Africa, Oct 10
- Rapport Therapeutics CEO Abraham Ceesay sells $143,272 in stockInvesting.com, Oct 10
- Form 144 RAPPORT THERAPEUTICS For: 6 October By Investing.comInvesting.com South Africa, Oct 7
- Rapport Therapeutics Price Target Announced at $65.00/Share by GuggenheimMoomoo, Oct 6
Rapport Therapeutics peers
Rapport Therapeutics’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| AMGNAmgen | Neutral | 25.5% below |
| GILDGilead Sciences | Neutral | 4.2% above |
| MRNAModerna | Neutral | 62.7% above |
| NTRANatera | Neutral | 10.3% above |
| IQVIQVIA | Neutral | 8.4% above |
| UTHRUnited Therapeutics | Neutral | 14.4% below |
A peer links to its own page where one exists.
Rapport Therapeutics stock FAQ
What is Rapport Therapeutics’s market cap?
Rapport Therapeutics’s market cap is $1.44B at the Oct 12, 2026 close of $30.15, with 47.98M shares outstanding.
What is the Rapport Therapeutics stock forecast?
The consensus analyst 12-month price target for Rapport Therapeutics is $63.04, +109.1% from the last close. Of the 10 firms that rated the stock in the last 90 days, 10 rate it a buy, 0 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
Is Rapport Therapeutics stock overvalued or undervalued?
On Gekko’s estimate Rapport Therapeutics is undervalued: the Oct 12, 2026 close of $30.15 is 34.4% below Gekko Fair Value of $45.97. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
When does Rapport Therapeutics report earnings next?
Rapport Therapeutics is expected to report on Nov 5, 2026, before the market opens (24 days away). Analysts expect earnings of −$1.21 per share. Rapport Therapeutics beat the earnings estimate in 5 of its last 8 reports, moving 4.9% on average across the report.
What is Rapport Therapeutics’s 52-week high and low?
Rapport Therapeutics’s 52-week high is $52.93 and its 52-week low is $23.75; it closed at $30.15 on Oct 12, 2026, +12.8% over the past year.
Is Rapport Therapeutics stock a buy right now?
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 2 of the 4 items with data read as supportive (gekkoindex and fair value), 1 as mixed (trend) and 1 as a headwind (earnings risk). The checklist is a description of current data, not a recommendation.
How this page works
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
See Rapport Therapeutics the way Gekko members do
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,408 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.